Brilinta ticagrelor regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on July 28 to discuss an NDA from AstraZeneca for Brilinta ticagrelor to reduce major adverse cardiac events in patients with acute co...